摘要
目的:探讨血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原(CA)125、CA199]对晚期结直肠癌患者靶向治疗临床疗效的评估价值。方法:选择2019年2~10月于我院接受化疗联合贝伐珠单抗靶向治疗的100例晚期结直肠癌患者为研究参与者,分别于治疗前、后均检测患者血清CEA、CA125、CA199表达水平。分析各血清肿瘤标志物水平与临床疗效的关系。结果:100例患者中,CR 0例,PR 65例,SD 26例,PD 9例,反应良好率为65.0%(65/100),反应不良率为35.0%(35/100)。反应良好组和反应不良组治疗前血清CEA、CA125、CA199水平比较,差异均无统计学意义,P>0.05;治疗后2组血清CEA、CA125、CA199水平均显著降低,但反应良好组各指标水平明显低于反应不良组,P<0.05。ROC曲线分析显示,血清CEA、CA125、CA199预测晚期结直肠癌靶向治疗反应良好的AUC依次为0.813、0.759、0.806,其中以CEA最高,Cutoff值取3.54 ng/mL时,灵敏度为86.52%,特异度为70.21%,三者联合检测时灵敏度、特异度均显著升高,分别为89.45%和92.01%。结论:血清CEA、CA125、CA199水平联合检测有望成为晚期结直肠癌靶向治疗临床疗效的预测指标。
Objective To explore the value of serum tumor markers CEA,CA125 and CA199 in evaluating clinical effect of targeted therapy for advanced colorectal cancer(ACRC). Methods Enrolled the 100 ACRC patients treated in authors' hospital with chemotherapy plus targeted therapy of bevacizumab into this research: before and after treatment respectively detect their the expression levels of CEA,CA125 and CA199,then, analyse the levels' relation to clinical effect. Results In the 100 cases, CR 0 case, PR 65 cases, SD 26 cases, PD 9 cases;the ratio of reaction was good of 65.0%(65/100),and unward of 35.0%(35/100),both groups' pre-treatment's levels had no statistical difference(P<0.05);but after treatment, above three factors' levels in both groups all declined significantly, only, good groups' levels were more significantly lower than unward group(P<0.05).ROC analysis showed the AUC of CEA,CA125 and CA199 in prognosing ACRC targted therapy's good in the order as 0.813,0.759,and 0.806 as the highest of CEA,given cutoff value=3.54 mg/mL,the sensitivity=86.52%,the specificity=70.21%,when combined detection of the three factors, just respectively(=)89.45%,(=)92.01%. Conclusion The combined detection of CEA,CA125,and CA199 could be the effectively prognosing indexes in evaluating clinical effect of ACRC treated with targeted therapy.
作者
陈素华
刘朵平
李陶威
王一迪
马天江
CHEN Su-hua;LIU Duo-ping;LI Tao-wei;WANG Yi-di;MA Tian-jiang(Dept.of Oncology,Luohe City's Central Hospital,Luohe,Henan 462000)
出处
《中国肛肠病杂志》
2023年第5期22-24,共3页
Chinese Journal of Coloproctology
